Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of rimegepant versus placebo for intermittent prevention of menstrual migraine in women
CTR20251258Phase 3Active
- Sponsor
- Pfizer
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rimegepant in Catamenial Migraine, sponsored by Pfizer. Started Sep 2025; status: active.
02
Drugs
rimegepant
03
Conditions
Catamenial Migraine
Beyond the preview
Go deeper on CTR20251258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251258.